Enasidenib Mesylate Patent Expiration
Enasidenib Mesylate is Used for treating relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation. It was first introduced by Bristol Myers Squibb
Enasidenib Mesylate Patents
Given below is the list of patents protecting Enasidenib Mesylate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Idhifa | US9732062 | Therapeutically active compounds and their methods of use | Sep 16, 2034 | Bristol Myers Squibb |
| Idhifa | US10093654 | Therapeutically active compounds and their methods of use | Aug 01, 2034 | Bristol Myers Squibb |
| Idhifa | US9738625 | Therapeutically active compounds and their methods of use | Aug 01, 2034 | Bristol Myers Squibb |
| Idhifa | US10294215 | Therapeutically active compounds and their methods of use | Jan 07, 2033 | Bristol Myers Squibb |
| Idhifa | US9512107 | Therapeutically active compositions and their methods of use | Jan 07, 2033 | Bristol Myers Squibb |
| Idhifa | US10610125 | Methods and compositions for cell-proliferation-related disorders | Jun 21, 2030 | Bristol Myers Squibb |
Enasidenib Mesylate's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List